BREAKING NEWS: New drug approved by the FDA for Duchenne muscular dystrophy. Learn more about this new treatment option.

Medical Educational Resource

We're accelerating the delivery of treatments and cures.

Limb-Girdle Muscular Dystrophy and the Diagnostic Odyssey

Activity Snapshot

Activity Type: 
On-Demand Webinar
Release Date: 
Monday, March 15, 2021
Expiration Date: 
Friday, March 15, 2024
Sponsor Information: 

This program is supported in part by an independent educational grant from Sarepta Therapeutics

Faculty

Matthew Wicklund, MD
Matthew Wicklund, MD
Professor of Neurology, Chief, Neuromuscular Section, University of Colorado - Anschutz Medical Campus
Limb-Girdle Muscular Dystrophy and the Diagnostic Odyssey
Activity Overview: 

Matthew Wicklund from University of Colorado Medicine provides an overview of distinguishing clinical and genetic features of the major subtypes of limb-girdle muscular dystrophy (LGMD) and the currently available diagnostic tests for identification of the various LGMD subtypes. The webinar provides practical guidance on the optimal workflow to obtain a definitive diagnosis, as well as a discussion of how an accurate diagnosis helps to inform the management plan.

Learning Objectives: 
  • Identify the different limb-girdle muscular dystrophy (LGMD) subtypes, including the genetic and pathophysiologic differences
  • Understanding the importance of obtaining a definitive genetic diagnosis
  • Understand the role of multidisciplinary care in optimizing treatment outcomes
Accreditation and Designation Statement: 

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of PeerPoint Medical Education Institute, LLC and the Muscular Dystrophy Association. The PeerPoint Medical Education Institute, LLC is accredited by the ACCME to provide continuing medical education for physicians.

The PeerPoint Medical Education Institute, LLC designates this live activity for a maximum of .75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

March 15, 2021 - March 15, 2024

How to Obtain CME credits : 

Once you have viewed the program, MDA will share back with you instructions for how to obtain your CME credits. If you have questions on this process, please reach out to cmemanagement@mdausa.org.

Faculty Disclosures: 

The following presenters, planners, editors, or staff have relevant financial relationships to disclose:

"I, or an immediate family member, have at present or have had within the last 12 months, the following affiliation with one or more organizations that could be perceived as a real or apparent conflict of interest in context to the design, implementation, presentation, evaluation, etc. of CME Activities."

Name: Matthew Paul Wicklund
Commercial Interest: Affinia Therapeutics
For what role?: Consulting
What was received?: Consulting fees

Commercial Interest: Amicus Therapeutics
For what role?: Consulting
What was received?: Consulting fees

Commercial Interest: ML Bio Solutions
For what role?: Consulting
What was received?: Consulting fees

Commercial Interest: Sarepta Therapeutics
For what role?: Consulting and research funding
What was received?: Consulting fees

All other presenters, planners, editors, or staff reported no relevant relationships with the following statement:

"I, or an immediate family member, do not have at present, or within the last 12 months, nor anticipate having financial interest, arrangement or affiliation with any organizations that could be perceived as a real or apparent conflict of interest in context to the design, implementation, presentation, evaluation, etc. of CME Activities."